AbelZeta Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 217

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $120M

  • Investors
  • 7

AbelZeta General Information

Description

Developer of proprietary cell therapies intended for the treatment of cancer and degenerative diseases. The company develops immune cell therapy for treating a broad range of cancers using cancer vaccines, enabling patients with safe treatments for serious conditions and diseases.

Contact Information

Website
abelzeta.com
Formerly Known As
ATC Technology, Cellular Biomedicine Group
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9605 Medical Center Drive
  • Suite 100
  • Rockville, MD 20850
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 9605 Medical Center Drive
  • Suite 100
  • Rockville, MD 20850
  • United States
+1 (240)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbelZeta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series A) 29-Sep-2021 $120M Completed Clinical Trials - Phase 1
10. Merger/Acquisition 19-Feb-2021 Completed Clinical Trials - Phase 1
9. Secondary Transaction - Open Market Completed Clinical Trials - Phase 1
8. PIPE 30-Jan-2018 Completed Clinical Trials - Phase 1
7. PIPE 28-Dec-2017 Completed Clinical Trials - Phase 1
6. PIPE 19-Apr-2016 Completed Clinical Trials - Phase 1
5. PIPE 07-Apr-2015 Completed Clinical Trials - Phase 1
4. PIPE 16-Jul-2014 Completed Clinical Trials - Phase 1
3. PIPE 11-Apr-2014 $6.91M $9.9M Completed Clinical Trials - Phase 1
2. PIPE 26-Jul-2013 $3M $3M Completed Clinical Trials - Phase 1
To view AbelZeta’s complete valuation and funding history, request access »

AbelZeta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of proprietary cell therapies intended for the treatment of cancer and degenerative diseases. The company deve
Drug Discovery
Rockville, MD
217 As of 2019

Abingdon, United Kingdom
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbelZeta Competitors (37)

One of AbelZeta’s 37 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
BeiGene Formerly PE-Backed Beijing, China
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Zynerba Pharmaceuticals Formerly VC-backed Plymouth, PA
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 37 competitors. Get the full list »

AbelZeta Patents

  • 76

    Total Documents Applications and Grants

  • Total Patents Families

  • 31

    Granted

  • 45

    Pending

  • Expiring in next 12 mo

AbelZeta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4469068-A2 Method for enriching tumor infiltrating lymphocytes Pending 28-Jan-2022
EP-4393467-A1 Device and method for fully enclosed and fully automatic dispensing of cells Pending 27-Aug-2021
US-20240352417-A1 Device and method for fully enclosed and fully automatic dispensing of cells Pending 27-Aug-2021
US-20230212255-A1 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof Pending 26-Feb-2021
EP-4284824-A2 Chimeric antigen receptors targeting cd20 Pending 27-Jan-2021 A61K40/4221
To view AbelZeta’s complete patent history, request access »

AbelZeta Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbelZeta Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alumni Ventures Venture Capital Minority
EastBridge Investment Group Corporation Minority
Sailing Capital PE/Buyout Minority
To view AbelZeta’s complete investors history, request access »

AbelZeta Investments & Acquisitions (5)

AbelZeta’s most recent deal was a Corporate Asset Purchase with University of South Florida (GVAX vaccine) for . The deal was made on 29-Jun-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
University of South Florida (GVAX vaccine) 29-Jun-2015 Corporate Asset Purchase Buildings and Property
Chinese PLA General Hospital (CAR-T cell technology) 09-Feb-2015 Corporate Asset Purchase Buildings and Property
Agreen Biotech 30-Sep-2014 Merger/Acquisition Other Healthcare Services
EastBridge Investment Group 06-Feb-2013 Merger/Acquisition Other Commercial Services
Lifetech Scientific 06-Jul-2004 Merger/Acquisition Surgical Devices
To view AbelZeta’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

AbelZeta ESG

Risk Overview

Risk Rating

Updated February, 02, 2021

32.64 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,189

Rank

Percentile

Pharmaceuticals

Industry

of 901

Rank

Percentile

Biotechnology

Subindustry

of 403

Rank

Percentile

To view AbelZeta’s complete esg history, request access »

AbelZeta FAQs

  • When was AbelZeta founded?

    AbelZeta was founded in 2001.

  • Where is AbelZeta headquartered?

    AbelZeta is headquartered in Rockville, MD.

  • What is the size of AbelZeta?

    AbelZeta has 217 total employees.

  • What industry is AbelZeta in?

    AbelZeta’s primary industry is Drug Discovery.

  • Is AbelZeta a private or public company?

    AbelZeta is a Private company.

  • What is AbelZeta’s current revenue?

    The current revenue for AbelZeta is .

  • How much funding has AbelZeta raised over time?

    AbelZeta has raised $120M.

  • Who are AbelZeta’s investors?

    Alumni Ventures, EastBridge Investment Group, and Sailing Capital have invested in AbelZeta.

  • Who are AbelZeta’s competitors?

    Adaptimmune Therapeutics, BeiGene, Sorrento Therapeutics, Zynerba Pharmaceuticals, and NexImmune are some of the 37 competitors of AbelZeta.

  • When was AbelZeta acquired?

    AbelZeta was acquired on 29-Sep-2021.

  • Who acquired AbelZeta?

    AbelZeta was acquired by GIC Private.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »